

FOI REF: 21/470

13<sup>th</sup> September 2021

Tel: 0300 131 4500

Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Can you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

• Abatacept [Orencia]	32
• Adalimumab [Humira]	31
• Adalimumab Biosimilars	264
• Apremilast [Otezla]	7
• Baricitinib [Olumiant]	90
• Certolizumab [Cimzia]	26
• Etanercept [Enbrel]	17
• Etanercept Biosimilars	227
• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	56
• Guselkumab [Tremfya]	0
• Infliximab [Remicade]	2
• Infliximab Biosimilars	73
• Ixekizumab [Taltz]	2
• Risankizumab [Skyrizi]	0
• Rituximab [MabThera]	12
• Rituximab Biosimilars	98
• Sarilumab [Kevzara]	2
• Secukinumab [Cosentyx]	85
• Tocilizumab [Ro Actemra]	67
• Tofacitinib [Xeljanz]	15
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	8

If I can be of any further assistance, please do not hesitate to contact me.

Cont.../

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)